Amicus Therapeutics Inc

Price Chart

Risk-Adjusted Performance

Also Listed On

Amicus Therapeutics Inc (FOLD) Price Performance

Amicus Therapeutics Inc (FOLD) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $14.41, down 0.14% from the previous close.

Over the past year, FOLD has traded between a low of $5.64 and a high of $14.43. The stock has gained 69.1% over this period. It is currently 155.5% above its 52-week low.

Amicus Therapeutics Inc has a market capitalization of $4.53B.

About Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.